Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Teva – Recall of losartan
June 11, 2019 - The FDA announced a consumer-level recall of Teva’s losartan tablets due to the detection of an impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), that is above the FDA’s interim acceptable exposure limit of 9.82 ppm.
